Patents by Inventor Konstantin G. Kousoulas
Konstantin G. Kousoulas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11975057Abstract: The present invention provides compositions for treating or preventing cancer and methods of using and making the compositions. The compositions comprise herpes simplex viruses comprising recombinant herpes simplex virus genomes. Further provided are recombinant herpes simplex virus genomes, viruses comprising the recombinant herpes simplex virus genomes, and cancer vaccines and other compositions comprising the viruses.Type: GrantFiled: August 1, 2019Date of Patent: May 7, 2024Assignee: Board of Supervisors of Louisiana State University Agriculture and Mechanical CollegeInventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, James Michael Mathis
-
Publication number: 20220241401Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.Type: ApplicationFiled: December 14, 2021Publication date: August 4, 2022Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Konstantin G. Kousoulas
-
Patent number: 11229697Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.Type: GrantFiled: February 7, 2020Date of Patent: January 25, 2022Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Konstantin G. Kousoulas
-
Publication number: 20210315984Abstract: The present invention provides compositions for treating or preventing cancer and methods of using and making the compositions. The compositions comprise herpes simplex viruses comprising recombinant herpes simplex virus genomes. Further provided are recombinant herpes simplex virus genomes, viruses comprising the recombinant herpes simplex virus genomes, and cancer vaccines and other compositions comprising the viruses.Type: ApplicationFiled: August 1, 2019Publication date: October 14, 2021Inventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, James Michael Mathis
-
Publication number: 20200345836Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.Type: ApplicationFiled: February 7, 2020Publication date: November 5, 2020Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Konstantin G. Kousoulas
-
Patent number: 10596253Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.Type: GrantFiled: October 1, 2018Date of Patent: March 24, 2020Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Konstantin G. Kousoulas
-
Patent number: 10328147Abstract: Embodiments of nucleic acids comprise a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. Also provided is a live-attenuated recombinant Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter.Type: GrantFiled: March 22, 2018Date of Patent: June 25, 2019Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGEInventor: Konstantin G. Kousoulas
-
Publication number: 20190091327Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.Type: ApplicationFiled: October 1, 2018Publication date: March 28, 2019Applicant: Board of Supervisors of Louisiana State University Agricultural and Mechanical CollegeInventor: Konstantin G. Kousoulas
-
Patent number: 10130703Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.Type: GrantFiled: May 8, 2015Date of Patent: November 20, 2018Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGEInventor: Konstantin G. Kousoulas
-
Publication number: 20180271974Abstract: The disclosure encompasses recombinant nucleic acids comprising a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. Also provided is a live-attenuated recombinant Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter.Type: ApplicationFiled: March 22, 2018Publication date: September 27, 2018Inventor: Konstantin G. Kousoulas
-
Publication number: 20170266275Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.Type: ApplicationFiled: May 8, 2015Publication date: September 21, 2017Inventor: Konstantin G. Kousoulas
-
Patent number: 8586028Abstract: A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral ?1 34.5 genes and other immediate early genes, which render the virus able to selectively replicate in cancer cells but not efficiently replicate in normal cells, and in which specific mutations have been introduced to enable the virus to spread among cancer cells by virus-induced fusion. Specifically, syncytial mutations have been introduced in the genes coding for glycoprotein B and glycoprotein K of the virus, enabling high replication and spread of the virus in cancer cells in the presence of substantially lower amounts of ?1 34.5 protein, which is required for optimum infectious virus produced and virus-induced cell fusion. These altered viruses or the isolated bacterial chromosomes could be used to treat various cancers including breast, liver, colon, and other tissues.Type: GrantFiled: May 9, 2008Date of Patent: November 19, 2013Assignee: Board of Supervisors of Lousiana State University and Agricultural and Mechanical CollegeInventor: Konstantin G. Kousoulas
-
Publication number: 20130202639Abstract: New recombinant oncolytic viral vectors have been constructed based on a known herpes simplex virus-1 with a single 34.5 gene and a synctial mutation (called OncSyn (OS) virus), which was designed to be more immunogenic than the parental OS virus largely due to deletion of the viral gene viral host shutoff (vhs) gene (the “OSV” virus). In another embodiment, the OSV virus was constructed to constitutively express 15-PGDH (the “OSVP” virus), the principal enzyme responsible for degradation of PGE2. OSVP was shown to decrease both breast tumors and prostate cancer tumors in mice models. In addition, OSVP was shown to trigger substantial inflammatory cytokine production and pro mote anti-tumor immune responsiveness. These altered viruses, OSV and OSVP, can be used to treat various cancers including breast, prostate, liver, colon, and other tissues. Other exogenous genes can be added to either OSV or OSVP to improve the therapeutic response.Type: ApplicationFiled: March 25, 2011Publication date: August 8, 2013Inventors: Konstantin G. Kousoulas, Jason D. Walker
-
Publication number: 20100297085Abstract: A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral ?1 34.5 genes and other immediate early genes, which render the virus able to selectively replicate in cancer cells but not efficiently replicate in normal cells, and in which specific mutations have been introduced to enable the virus to spread among cancer cells by virus-induced fusion. Specifically, syncytial mutations have been introduced in the genes coding for glycoprotein B and glycoprotein K of the virus, enabling high replication and spread of the virus in cancer cells in the presence of substantially lower amounts of ?1 34.5 protein, which is required for optimum infectious virus produced and virus-induced cell fusion. Other known syncytial mutations could also be introduced that would render the virus able to cause extensive virus-induced cell fusion. In addition, other known mutations can be introduced to limit the spread of the virus to the nervous system.Type: ApplicationFiled: May 9, 2008Publication date: November 25, 2010Inventor: Konstantin G. Kousoulas
-
Patent number: 7279171Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.Type: GrantFiled: August 11, 2003Date of Patent: October 9, 2007Assignee: Board of Supervisors of Louisiana State University and Mechanical CollegeInventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, Abolgasem Baghian, Thomas N. Tully, Jr.
-
Patent number: 7202225Abstract: The present invention relates to compositions and methods for delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a delivery composition comprising an administerable admixture of an effective amount of a nucleic acid sequence and an effective amount of a surface active nonionic block copolymer having the following general formula: HO(C2H4O)b(C3H6O)a(C2H4O)bH wherein a is an integer such that the hydrophobe represented by (C3H6O) has a molecular weight between approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 25%.Type: GrantFiled: December 9, 1999Date of Patent: April 10, 2007Inventors: R. Martin Emanuele, Konstantin G. Kousoulas, Hameedsulthan S. Allaudeen
-
Patent number: 6933286Abstract: The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. In particular, compositions and methods using biologically active nononic reverse block copolymers are described. The reverse copolymers have an inner core of polyoxyethylene (POE) that is flanked on either end by polyoxpropylene (POP). The reverse block copolymers have the following formula: wherein “b” represents a number such that the molecular weight of the hydrophobe (C3H6O)b is between approximately 750 and 20,000 Daltons and “a” represents a number such that the percentage of hydrophile (C2H4O)a is between approximately 1% and 90% of the weight of the block copolymer.Type: GrantFiled: August 14, 2001Date of Patent: August 23, 2005Inventors: R. Martin Emanuele, Mark Newman, Konstantin G. Kousoulas, Hameedsulthan S. Allaudeen
-
Publication number: 20040248833Abstract: The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences.Type: ApplicationFiled: August 2, 2004Publication date: December 9, 2004Inventors: R Martin Emanuele, Konstantin G Kousoulas, Hameedsulthan S Allaudeen, Mark Newman
-
Patent number: 6605287Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.Type: GrantFiled: August 28, 1998Date of Patent: August 12, 2003Assignee: Board of Supervisors of Louisiana State University & Agricultural and Mechanical CollegeInventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, Abolgasem Baghian, Thomas N. Tully, Jr.
-
Publication number: 20020136742Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.Type: ApplicationFiled: August 28, 1998Publication date: September 26, 2002Inventors: KONSTANTIN G. KOUSOULAS, VLADIMIR N. CHOULJENKO, ABOLGASEM BAGHIAN, THOMAS N. TULLY, JR.